HRS 2020: Boston Scientific’s Next-Gen LAAC Device Hits Targets In PINNACLE FLX Trial

The PINNACLE FLX trial of the next-generation WATCHMAN left atrial appendage closure device met its primary safety and effectiveness endpoints with a low adverse event rate of 0.5%.

Minimally invasive transcatheter closure treatment for left atrial appendage LLA with occluder, using a minimally invasive procedure treatment of structural heart disease

One-year results from the PINNACLE FLX trial show Boston Scientific Corp.’s WATCHMAN FLX system can safely and effectively close the left-atrial appendage closure device in patients with non-valvular atrial fibrillation.

Shephal Doshi of the Pacific Heart Institute in Santa Monica, CA, presented the 12-month follow-up data from the trial during...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D